Serum perampanel levels in patients with seizures are not affected by hemodialysis
Epilepsia Open · 2024
DOI: 10.1002/epi4.12996 ↗Kurz gefasst
Fachartikel in der Zeitschrift Epilepsia Open, 2024. Verfasst von Yusuke Nakazawa und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Kokura Memorial Hospital, Kitakyushu, Japan. Hauptthemen laut MEDLINE: Renal Dialysis, Pyridones, Anticonvulsants, Nitriles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Perampanel belongs to a novel class of antiseizure medications (ASMs). Studies examining the effect of hemodialysis on perampanel serum levels in clinical settings are lacking. We aimed to evaluate the changes in serum perampanel levels during hemodialysis. We studied patients with seizures who received oral perampanel between April 2020 and March 2023 and whose serum concentration of perampanel was measured before and after hemodialysis. We analyzed the serum concentrations of levetiracetam and lacosamide for comparison. Fourteen patients, with a mean age of 76.1 ± 7.88 years, were included. The dose of perampanel was 2.14 ± 1.27 mg. The hemodialysis clearance rate of perampanel, levetiracetam, and lacosamide was 0 ± 13%, 69 ± 11%, and 59.6 ± 8.2%, respectively. The post‐dialysis CD ratio decreased significantly with levetiracetam but not with perampanel. Adverse but acceptable effects of perampanel were observed in two patients. The serum concentrations of several ASMs have been shown to be reduced during hemodialysis. Our study revealed that the serum perampanel concentration does not decrease during hemodialysis. Owing to the low rate of adverse effects and the stability of perampanel serum concentration during hemodialysis, perampanel could be a favorable choice as an ASM for patients with seizures undergoing hemodialysis. Plain Language summary Our study looked at how hemodialysis affects the serum levels of perampanel, a new type of medication for seizures. In 14 patients who started treatment between April 2020 and March 2023, perampanel serum levels did not decrease during hemodialysis, unlike other seizure medications. This shows that perampanel can be a good option for patients with seizures who need hemodialysis, with fewer side effects compared to other medications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Kokura Memorial Hospital, Kitakyushu, Japan.
- Department of Neurosurgery, Kokura Memorial Hospital, Kitakyushu, Japan.
ORCID-Profile: Yusuke Nakazawa
Zitieren
APA
Nakazawa, Y., Shiraishi, W., Matsuyoshi, A., Inamori, Y., Mitani, K., Ando, N., Shiomi, K., Morita, T., Koga, N., Agawa, Y., Miyata, T., Ogura, T., & Hatano, T. (2024). Serum perampanel levels in patients with seizures are not affected by hemodialysis. Epilepsia Open. https://doi.org/10.1002/epi4.12996
Vancouver
Nakazawa Y, Shiraishi W, Matsuyoshi A, Inamori Y, Mitani K, Ando N, et al. Serum perampanel levels in patients with seizures are not affected by hemodialysis. Epilepsia Open. 2024. doi:10.1002/epi4.12996
BibTeX
@article{Nakazawa2024,
author = {Nakazawa, Yusuke and Shiraishi, Wataru and Matsuyoshi, Ayano and Inamori, Yukiko and Mitani, Koki and Ando, Narutada and Shiomi, Koji and Morita, Takao and Koga, Noriyuki and Agawa, Yuji and Miyata, Takeshi and Ogura, Takenori and Hatano, Taketo},
title = {Serum perampanel levels in patients with seizures are not affected by hemodialysis},
journal = {Epilepsia Open},
year = {2024},
doi = {10.1002/epi4.12996}
}
EUVIMED